Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?

G. Cserni, Monika Francz, E. Kálmán, Gyöngyi Kelemen, Detre Csaba Komjáthy, I. Kovács, J. Kulka, László Sarkadi, N. Udvarhelyi, László Vass, András Vörös

Research output: Article

25 Citations (Scopus)

Abstract

Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1%; range of the rate per department: 0.3-7.1%.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1% cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.

Original languageEnglish
Pages (from-to)663-668
Number of pages6
JournalPathology and Oncology Research
Volume17
Issue number3
DOIs
Publication statusPublished - szept. 2011

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Phenotype
Neoplasms
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they? / Cserni, G.; Francz, Monika; Kálmán, E.; Kelemen, Gyöngyi; Komjáthy, Detre Csaba; Kovács, I.; Kulka, J.; Sarkadi, László; Udvarhelyi, N.; Vass, László; Vörös, András.

In: Pathology and Oncology Research, Vol. 17, No. 3, 09.2011, p. 663-668.

Research output: Article

Cserni, G. ; Francz, Monika ; Kálmán, E. ; Kelemen, Gyöngyi ; Komjáthy, Detre Csaba ; Kovács, I. ; Kulka, J. ; Sarkadi, László ; Udvarhelyi, N. ; Vass, László ; Vörös, András. / Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?. In: Pathology and Oncology Research. 2011 ; Vol. 17, No. 3. pp. 663-668.
@article{4cdccb7f411448aebe4d27da4b342f72,
title = "Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?",
abstract = "Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1{\%}; range of the rate per department: 0.3-7.1{\%}.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1{\%} cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.",
keywords = "Breast cancer, Estrogen receptor, Estrogen receptor-negative progesterone receptor-positive breast cancer, Immunohistochemistry, Progesterone receptor",
author = "G. Cserni and Monika Francz and E. K{\'a}lm{\'a}n and Gy{\"o}ngyi Kelemen and Komj{\'a}thy, {Detre Csaba} and I. Kov{\'a}cs and J. Kulka and L{\'a}szl{\'o} Sarkadi and N. Udvarhelyi and L{\'a}szl{\'o} Vass and Andr{\'a}s V{\"o}r{\"o}s",
year = "2011",
month = "9",
doi = "10.1007/s12253-011-9366-y",
language = "English",
volume = "17",
pages = "663--668",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?

AU - Cserni, G.

AU - Francz, Monika

AU - Kálmán, E.

AU - Kelemen, Gyöngyi

AU - Komjáthy, Detre Csaba

AU - Kovács, I.

AU - Kulka, J.

AU - Sarkadi, László

AU - Udvarhelyi, N.

AU - Vass, László

AU - Vörös, András

PY - 2011/9

Y1 - 2011/9

N2 - Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1%; range of the rate per department: 0.3-7.1%.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1% cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.

AB - Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1%; range of the rate per department: 0.3-7.1%.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1% cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.

KW - Breast cancer

KW - Estrogen receptor

KW - Estrogen receptor-negative progesterone receptor-positive breast cancer

KW - Immunohistochemistry

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=80052756449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052756449&partnerID=8YFLogxK

U2 - 10.1007/s12253-011-9366-y

DO - 10.1007/s12253-011-9366-y

M3 - Article

C2 - 21267685

AN - SCOPUS:80052756449

VL - 17

SP - 663

EP - 668

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -